Survivin is highly expressed in most human tumors and fetal tissue, and absent in terminally differentiated cells. It promotes tumor cell proliferation by negatively regulating cell apoptosis and facilitating cell division. Survivin's selective expression pattern suggests that it might be a suitable target for cancer therapy, which would promote death of transformed but not normal cells. This was tested using artificial microRNAs (amiRNAs) targeting survivin. After screening, two effective amiRNAs, which knocked down survivin expression, were identified and cloned into a replication-defective adenoviral vector. Tumor cells infected with the recombinant vector downregulated expression of survivin and underwent apoptotic cell death. Further studies showed that apoptosis was associated with increases in caspase 3 and cleaved Poly (ADP-ribose) polymerase, and activation of the p53 signaling pathway. Furthermore, amiRNA treatment caused blockade of mitosis and cell cycle arrest at the G2/M phase. In vivo, survivin-targeting amiRNAs expressed by adenoviral vectors effectively delayed growth of hepatocellular and cervical carcinomas in mouse xenograft models. These results indicate that silencing of survivin by amiRNA has potential for treatment of cancer.
Introduction
Cancer cells are characterized by defective regulation of proliferation and apoptosis resulting in uncontrolled cell growth, which eventually leads to the demise of the organism. 1 Several mechanisms reduce apoptosis of cancer cells thereby aberrantly prolonging their life span. 2, 3 Survivin, also called baculoviral inhibitor of apoptosis repeat-containing 5 or BIRC5, is the smallest member of the inhibitor of apoptosis family. It is evolutionarily highly conserved and its expression is restricted to tumor cells and fetal tissues but missing in terminally differentiated cells. Expression of survivin is controlled by the cell cycle and it is only detectable in cells during G2/M transition. Survivin's main role is to block apoptosis by inhibiting Fas and Bax pathways and the activity of caspases 3 and 7. In addition, survivin localizes to the mitotic spindle during cell division and may thereby promote proper separation of chromosomes. 2, [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] As survivin is selectively expressed in tumors, it provides a suitable target for therapy as has been shown in vitro and in vivo.
RNA interference (RNAi) has been widely applied to biological studies and it provides a promising therapeutic strategy to human disease. MicroRNAs (MiRNAs), small single-stranded sequences of ~22 nucleotides, are considered to play important roles in cell proliferation, apoptosis, and cancer progression. They are characterized by their expression patterns, which are developmentally regulated, tissue specific, or steadily expressed in the whole organism. [15] [16] [17] Exogenous RNAi has been expressed in mammalian cells and animals in response to artificial microRNA (amiRNA) transcripts among a background of cellular miRNAs. 18 AmiRNAs are regarded as regulatory molecules by sequence-specific base pair that binds to the targeted mRNA, contributing to direct mRNA degradation or translational inhibition. 19, 20 Owing to the specificity and efficiency in gene silencing, it has been increasingly investigated whether amiRNA targeted to oncogenes can correct aberrant transcript levels in cancer cells. [21] [22] [23] [24] Therefore, expression of survivin can be manipulated by amiRNAs that target the survivin transcripts.
To test if this affects tumor cell survival and growth, we developed E1-deleted adenoviral vectors expressing survivin-specific amiRNAs. In vitro and in vivo experiments showed that repressing survivin in hepatocellular carcinoma and cervical cancer cell lines resulted in their diminished proliferation and increased apoptosis in culture and in reduced tumor progression in xenograft mouse models. Overall, these data show that survivin-specific amiRNA gene transfer may provide treatment options for a wide range of human malignancies.
Results

Survivin-targeting amiRNAs inhibit cancer cell proliferation
To identify amiRNAs that could potentially reduce expression of survivin, we established a screen to test nine candidate amiRNAs. AmiRNA clones were expressed in the backbone of the BLOCK-iT miR RNAi expression vector, which can be transfected transiently into cultured cells. A dramatic change was observed by 72 hours in transfected HEK 293 cells, in which survivin mRNA was reduced by six of the nine amiRNAs (Figure 1a) . The same amiRNAs also reduced the expression of survivin in the hepatocellular carcinoma cell line Huh7 and the cervical carcinoma cell line HeLa (Figure  1b,c) . Reduced levels of survivin transcripts corresponded to reduced levels of survivin protein in all of the three cell lines (Figure 1d) . These results show that survivin expression can readily be reduced by specific amiRNAs.
As transduction of cancer cells with plasmid expressing the survivin-targeting amiRNAs yielded promising results, we next tested a more efficient adenovirus (Ad) vector gene delivery system. To this end, we constructed and purified two recombinant Ad vectors expressing amiRNAs MiSur5 and MiSur6 (Ad-MiSur5, Ad-MiSur6). Next, we tested the effect of Ad-MiSur5 and Ad-MiSur6 vectors on levels of survivin mRNA in Huh7 cells in a time-dependent as well as dosedependent manner. As shown in Figure 2a , infection of cells with Ad-MiSur5 or Ad-MiSur6 led to a three-to fivefold decrease in survivin mRNA compared to that in cells infected with a control vector. Reduction in survivin transcripts was already observed after 24 hours but increased over time. The effect was dose-dependent and the most pronounced reductions in survivin transcripts were obtained with the 10 10 vp dose of Ad vectors. Suppression of survivin expression led to cells death (Figure 2b,c) and reduction in the cells ability to form colonies (Figure 2d , e) as has been described previously. 6, 25 The effect of Ad vector-delivered surviving-targeting amiRNA on proliferation of Huh7 and HeLa cells was further assessed with a MTT assay. Again results confirmed that MiSur5 or MiSur6 inhibited cell proliferation in a dose-and time-dependent manner. Complete inhibition of proliferation of either of the cell lines was achieved by 72 hours after infection of cellskjkj with 10 10 vp of Ad vectors (Figure 2f,g ). In summary, two of the Ad-expressed amiRNAs, MiSur5 or MiSur6, show substantial inhibition of tumor cell growth and survival in vitro.
Survivin-targeting amiRNAs induce cancer cell apoptosis by the activation of cleaved caspase 3 and the elevation of proapoptotic Bim protein
It is known that survivin prevents apoptosis of human cancer cells. 5, 26 To test if knock-down of survivin suppresses tumor cell growth by inducing cell death, we analyzed apoptosis of Huh7 and HeLa cells that were infected with Ad-MiSur5, AdMiSur6, or a control vector. As shown in Figure 3a ,b, both amiRNA expressing vectors induced apoptosis of the cancer cells as evidenced by positive staining for annexin alone (early apoptosis) or annexin with propidium iodide (PI) (late apoptosis).
We examined if treatment with survivin-targeting amiRNAs caused over time accumulation of cleaved caspase 3. AdMiSur5-or Ad-MiSur6-treated Huh7 (Figure 3c ) and HeLa (Figure 3d ) cells showed significantly augmented levels of cleaved caspase 3, which increased over time. Increases in activated caspase 3 were more pronounced in cells infected with high doses of vector. Other apoptosis markers such as Bim and cleaved Poly (ADP-ribose) polymerase also became augmented (Figure 3e,f) . Protein was detected by western blot with β-actin as a loading control. Columns, mean; bars, ± SEM; *P < 0.05; **P < 0.01; ***P < 0.001 versus controls. Each data point represents the average of five repeated samples, and each experiment was performed three times. Survivin-targeting amiRNAs arrest cell cycle in G2/M Survivin associates with microtubules of the mitotic spindle at the start of cell division and is needed to ensure proper separation of chromosomes into the two daughter cells. 13, 27 In the absence of surviving, cells are unable to pass through mitosis. We confirmed that high dose of Ad vector encoding survivin-targeting amiRNAs caused accumulation of cells at the G2/M phase (Figure 4a,b) and sub-G1 phase (apoptosis).
Expression of survivin is inhibited by p53 and it is feasible that in turn survivin represses p53 expression. Indeed Ad-MiSur5 or Ad-MiSur6 infected Huh7 and HeLa cells had increased levels of p53, phosphorylated p53, and p21 a downstream target of p53 (Figure 5a,c) , thus suggesting that cell cycle arrest depended on the p53 pathway. Furthermore, levels of the retinoblastoma protein (Rb) increased while phosphorylated Rb and cyclin E and D declined (Figure 5b,c) . We repeated the experiment with HeLa xenografts and again observed upon Ad vector treatment a delay in tumor progression (Figure 7a ) associated with an increase in tumor cell apoptosis (Figure 7b) .
Overall, these results show that survivin targeting amiRNAs delivered by Ad vectors directly into the tumor significantly extend survival of tumor bearing mice by causing massive tumor cell apoptosis.
Discussion
Survivin is considered to be a potential target for anticancer therapy. 8, [28] [29] [30] Attenuation of survivin expression in function has been shown to induce apoptosis and inhibit tumor growth in multitypes of cancer by using antisense oligonucleotides, small interfering RNAs (siRNAs), or dominant-negative mutants in vivo. [31] [32] [33] [34] Previous studies have shown that elimination of survivin expressing tumors cells by cytolytic CD 8+ T cells, which spontaneously develop in some cancer patients or can be induced by specific vaccines provides clinical benefits. 30, 35, 36 Silencing of survivin by siRNA has been demonstrated to inhibit tumor growth by triggering apoptosis or overcoming drug resistance. 32, 33 It is commonly used for in vitro investigations to transfect siRNAs for direct targeting survivin mRNA. However, this approach has many limitations including disadvantages pharmacokinetic profile, ineffective delivery into cells, poor stability in vivo, and difficulty to perform clinical trials. The vector-based systems of high efficiency that facilitate engineered shRNA expression are driven by polymerase III promoter. 37, 38 Unfortunately, there are some limits on their tissue-specific and cytotoxicity.
Previous studies have shown that key cellular pathways and checkpoint for virus replication are controlled by miRNAs. In eukaryotic organisms, siRNAs can be formed from double-stranded RNAs by an enzyme Dicer, RNase III family member, and then incorporate into an enzyme complex, RISC, to target mRNA complementary to the siRNA for specific cleavage and degradation. Since translational arrest of target mRNAs is processed only by partial complementarity to the miRNA, which is often sufficient for effective regulation, allowing a single miRNA to regulate large numbers of targets. The amiRNAs are siRNA sequence embedded in native pri-miRNAs scaffold involving a hairpin structure and driven by polymerase II promoter. The stem-loop structure pri-miRNA is cleaved by nuclear RNase III Drosha to generate a small hairpin precursor, 70 nucleotides pre-miRNAs. With the export from nuclear, the pre-miRNAs are processed by Dicer into mature miRNA molecule and incorporated into miRNA-containing RNA-induced silencing complex. Several studies illustrated a higher efficiency and safety in the use of amiRNAs comparing with shRNAs. 19 Recently, amiRNAs have been applied to mammalian cell targets as a new tool for repressing gene expression, not only a single gene, but multigenes. 18, 39 This in turn has led to the development of amiRNAs to silence oncoproteins that are essential for tumor cell proliferation. Here we focus on survivin, which is a highly suited target for cancer therapy as it is selectively expressed in a wide variety of cancer cells but virtually absent in terminally differentiated normal tissues.
MiRNAs are undergoing clinical testing. Two general approaches are being tested, miRNA agonists to knockdown the functions of oncoproteins to which tumor cells have become addicted or miRNA antagonists to restore loss of function of tumor suppressors. 40, 41 MiRNAs are also tested as treatments for chronic infections or degenerative diseases. [42] [43] [44] MiRNAs are attractive therapeutics; delivery methods are well established through already gained experience with silencing RNA. Also, they are expected to cause minimal side effects as they are already expressed in Agonists that being tested include let-7 for treatment of lung cancer, mi-R16, miR-34a, and miR-146a for treatment of solid cancers. 41, 45 Delivery methods to reduce off target effects need to be improved and chemical modification to increase the amiRNA's stability, target specificity, and ability to cross membranes are being developed. Overall, targeting miRNAs is evolving into a very promising approach for cancer treatment, and as shown here, knockdown of survivin through amiRNA can at least in preclinical models reduce progression of different solid tumors.
In this study, we developed a strategy for cancer therapy based on Ad vector delivery of survivin-targeting amiRNAs. In the past, viral vectors have predominantly used in anticancer therapy. 46, 47 Virus-based vaccine is employed for the delivery of exogenous DNA sequenses into specific tumor. Ad vector has been attracted much attentions on cancer gene therapy due to its large cloning capacity, efficient transduction, and producing high-titer stocks. 48, 49 Although Hela expresses wild-type p53/p21, Huh7 expresses mutant p53 and defective p21, our results show that survivin-targeting amiRNAs reduced proliferation of two very different human carcinoma cells. We performed cell cycle studies to illustrate common apoptosis mechanisms at increasing p53/p21 protein level. Reduced cell growth was linked to an arrest of cells in the G2/M phase, which could have been caused by increased activation of p53 pathways suggesting that the G2/M arrest is dependent on p53 activation. The important tumor suppressor, p53 activates a series of cellular genes in the checkpoint of G2/M. We also demonstrated that amiRNAs could induce p53 phosphorylation at Ser 15, a hint of apoptosis by inhibiting survivin. It will be important to detect whether survivin-targeting amiRNAs-induced p53 upregulation and cleaved Poly (ADP-ribose) polymerase activation is confined to cancer cells. In addition, as it is crucial for cancer remission, knock-down of survivin causes increased tumor cell apoptosis. Most importantly, these observations from in vitro cultures could be extended to in vivo human cancer models of immunocompromised mice. 
Materials and Methods
Artificial miRNA design and generation of plasmids microRNA. Artificial miRNAs were designed by BLOCK-iT Pol II miR RNAi Designer (Life Technologies, Grand Island, NY), which identifies an optimal target site within a gene to induce gene knockdown. Nine appropriate sequences of single-stranded oligonucleotides were generated and annealed, and respectively cloned into the miRNA expression vector pcDNA 6.2-GW/miR (Invitrogen, Carlsbad, CA) following the protocol of BLOCK-iT Pol II miR RNAi Expression Vector Kit (Invitrogen).
Cell lines, transfection, and bacterial strains. Human embryonic kidney 293 (HEK 293) cells, human hepatocellular carcinoma cells (Huh7), and human cervical cancer cells (Hela) were grown in Dulbecco's modified Eagle's medium medium with 10% fetal bovine serum and 100 units/ml of penicillin. All cells were maintained in a humidified 37 °C incubator with 5% CO 2 . Transfections were carried out using Lipofectamine 2000 (Invitrogen) for HEK 293 cells or Lipofectamine LTX (Invitrogen) for Huh7 cells and Hela cells, according to the manufacturer's instructions. pcDNA 6.2-GW/miR plasmids and pShuttle plasmids (Clonetech, Mountain View, CA) were transformed into the bacterial strain TOP10 (Invitrogen) at 37 °C in S.O.C medium.
Construction and production of recombinant adenoviruses.
The expression cassettes of artificial miRNAs from pcDNA 6.2-GW/miR plasmids were amplified by polymerase chain reaction (PCR) and restriction enzyme sites Mfe I on the 5′ UTR and Pst I on the 3′ UTR were added, respectively, then subcloned into the pShuttle vector (sense, 5′-GCT-GCA-ATT-GGA-TGT-ACG-GGC-CAG-ATA-TAC-G-3′; antisense, 5′-CCA-GCT-GCA-GGC-TAT-GAC-CAT-GTA-ATA-CG-3′). After digestion with I-CeuI and PI-SceI, the amiRNA expressing cassettes were cloned from pShuttle into the E1 domain of the molecular clones of adenovirus of human serotype 5 (Ad). Recombinant Ad vectors were rescued by transfection of plasmid DNA into HEK 293 cells. The Ad vectors were purified by cesium chloride density-gradient centrifugation and virus particle content was determined by spectrophotometry (260 nm). The plasmid construct and recombinant adenovirus genome of each vector were confirmed by restriction enzyme digestions. 50 Real-time PCR. Total cellular RNA was extracted from each sample (~1 × 10 6 cells) using Trizol Reagent (Invitrogen). RNA (1 μg) from each sample was reverse transcribed using a high-capacity RNA-to-cDNA synthesis kit (Applied Biosystems, Foster City, CA), according to the manufacturer's protocol. A total of 15 μl of specific real-time PCR mixture (7.5 μl SYBR Green PCR Master Mix, 0.5 μl of 10 μmol/l forward and reverse primers each, 1.5 μl of H 2 O, and 5 μl of cDNA), surviving transcripts, and actin were amplified from the cDNA in triplicate experiments by FastStart Universal SYBR Green Master (Roche Diagnostics, Indianapolis, IN). The survivin primers were: sense, 5′-TTC-AAG-GAG-CTG-GAA-GGC-T-3′, antisense, 5′-CAC-TTT-CTC-CGC-AGT-TTC-CTC-AA-3′. The actin primers were: sense, 5′-ACC-GAG-CGC-GGC-TAC-AG-3′, antisense, 5′-CTT-AAT-GTC-ACG-CAC-GAT-TTC-C-3′. The ABI 7900HT Fast Realtime PCR system (Applied Biosystems) was used for PCR amplification and detection. The relative quantitative PCR program consisted of the initial process of 10 minutes at 95 °C and 40 cycles of 1 minute at 95 °C, 30 seconds at 55 °C, and 30 seconds at 72 °C. Target transcript levels were calculated from the comparative C t method and were normalized by actin products in each sample. Melting curves for each PCR mixture were generated to ensure the purity of amplification products.
Western blot analysis. Levels of survivin protein were measured by western blot analyses. Plasmid transfected or virusinfected cells were lysed in a radioimmunoprecipitation assay lysis buffer containing 50 mmol/l Tris (pH 7.4), 150 mmol/l NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 1 mmol/l ethylenediaminetetraacetic acid (pH 8.0), 2 mmol/l phenylmethylsulfonyl fluoride, 2 μg/ml aprotinin, 2 μg/ml leupeptin, 1 mmol/l Na 3 VO 4 , protease inhibitor cocktail (Roche), and the phosphatase inhibitor cocktail (Roche). Cell debris was removed by centrifugation after freeze-thawing of cells and protein concentrations were measured using the bicinchoninic acid protein assay (Pierce, /well) were seeded in 96-well plates and cell survival was determined by an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium) assay, as previously described. 52 Treated and control cells were incubated at 37 °C for 4 hours, after adding 5 μg/ml MTT reagent and cleavage was determined by using a multiwell scanning spectrophotometer (Thermo Fisher Scientific) at a wavelength of 490 nm. 53 The survival of amiRNA-treated cells was normalized to control cells. The growth-inhibitory effect was measured for 3 consecutive days by MTT assay. The experiments were performed in eight replicates for each sample, and repeated in triplicate.
Colony formation assays. Cells (1 × 10 3 /well) were seeded in six-well plates and infected with different concentrations (10 9 and 10 10 vp) of recombinant Ad vectors expressing survivin-targeting amiRNAs and scramble controls. Each group of infected cells was cultured in medium with 5% FBS in triplicate wells. Three weeks after infection, colonies were fixed with cold methanol and stained with a Giemsa solution, and then scored using an Elispot reader. 54, 55 The total number of surviving cells, extrapolated from amiRNA-treated cells, when compared with cells treated with scramble amiRNAs, was plotted on a dose-response column chart.
Caspase 3 activity assay. Caspase 3 activity was assayed based upon caspase 3 hydrolysis of peptide substrate acetylAsp-Glu-Val-Asp p-nitroanilide (Ac-DEVD-pNA), to release p-nitroaniline (pNA) according to the caspase 3 colorimetric assay (Sigma-Aldrich). 56, 57 AmiRNA-treated and control cells were centrifuged and supernatants removed. Cell pellets were washed twice with ice-cold PBS, resuspended in lysis solution, and incubated on ice for 15 minutes. The lysates were centrifuged, the appropriate substrates were added, and the reaction solution was incubated at 37 °C for 2 hours. Caspase 3 activity was measured at a wavelength of 405 nm.
Flow cytometry analysis for apoptosis and cell cycle. Trypsinized cancer cells were washed twice with ice-cold PBS and incubated with annexin-V-FITC/PI (Sigma-Aldrich) in binding buffer 58 ; cell fluorescence was immediately determined by a FACScan machine (BD, Franklin Lakes, NJ).
For cell cycle analysis, trypsinized cancer cells were washed twice with ice-cold PBS and fixed with 70% ethanol at 4 °C overnight. Cells were washed with PBS twice and resuspended in 500 μl of 50 μg/ml PI (Sigma-Aldrich) and 100 μg/ml RNase A (Life Technologies, Carlsbad, CA). Cell cycles were determined by measuring DNA content of each cell population by flow cytometry. were suspended in 100 μl matrigel (BD) and injected subcutaneously into the flanks of nude mice at 7-8 weeks of age. When tumors were palpable ~10 days after cell implantations, mice were randomly distributed into treated (n = 10) and control (n = 10) groups receiving an injection of 10 10 vp recombinant Ad vector expressing surviving-targeting amiRNAs or scramble amiRNAs, respectively. Tumor size was recorded with the formula "a × b 2 × 0.5" (a is the longest and b is the shortest radius of the tumor in millimeters as measured by a caliper in 2-day intervals). 59 Half of the mice in each group were sacrificed 18 days after initial treatment; the others were maintained until excessive tumor burden required their euthanasia (Supplementary Figure S2) . All animal experiments were approved by the Institutional Animal Care and Use Committee at the Institut Pasteur of Shanghai and the animals were cared for in accordance with the institutional guidelines.
Histology and immunohistochemistry. Tumors were fixed with 1 ml 4% PFA overnight and dehydrated in ethanol, paraffinembedded, and cut into 5 μm sections after hematoxylin and eosin (H&E) staining. Immunohistochemistry was performed as previously described. 60 Briefly, sections were microwaved for 25 minutes in 0.01 mol/l citrate buffer (pH = 6.0), cooled, treated with normal goat serum (1:5) for 20 minutes, and incubated with the primary antibody (cleaved-caspase 3, Cell Signaling Technology, Beverly, MA; Ki67 and NCL-ki67p, Leica Biosystems, Newcastle Upon Tyne) at 4 °C overnight. Biotinconjugated second rabbit anti-mouse antibody was applied for 15 minutes at 37 °C, followed by incubation of sections with enzyme-conjugated peroxidase-streptavidin for 15 minutes at 37 °C. Sections were washed thoroughly with TBST after each incubation. Immunoreactivity was visualized for 3 minutes with a diaminobenzidine substrate kit that stained positive cells brown. Sections were dehydrated in 100% (v/v) alcohol, cleaned in toluene, and mounted with permount.
Statistical analysis. All graphs were created with Graphpad Prism 5 software (GraphPad Software, La Jolla, CA) and statistical analyses were performed with SPSS software version 16.0 (SPSS, Chicago, IL). ANOVA was applied to compare relative mRNA levels between groups. A P value of less than 0.05 was considered statistically significant. Figure S1 . Female nude mice inoculated subcutaneously with Huh7 cells and then infected with 10 10 vp Ad-MiSur5, AdMiSur6, control vectors are shown. Figure S2 . Depletion of survivin prolongs lifetime of xenograft nude mice.
Supplementary material
